Abstract: A MASH type sigma delta AD converter includes a modulator, an analog filter filtering an extraction signal obtained by extracting a probe signal and an quantization error generated in a quantizer within a sigma delta modulator, a low speed AD converter performing an AD conversion of an output signal of the analog filter, a first adaptive filter searching for a transfer function of the sigma delta modulator, a second adaptive filter searching for a transfer function from an output of the modulator to the low speed AD converter via the analog filter, and a noise cancellation circuit cancelling the probe signal and the quantization error included in an output signal of the quantizer using the search results by the first and second adaptive filters.

Abstract: A conventional analog-to-digital conversion circuit has a problem that conversion errors cannot be suppressed.

Abstract: A modulator includes an analog integrator including an analog circuit and a quantizer quantizing its output signal. An external input signal is input thereto. A modulator is coupled to the latter stage of the modulator, and includes a quantizer. A probe signal generation circuit injects a probe signal to the modulator. An adaptive filter searches for a transfer function of the modulator by observing an output signal of the quantizer in accordance with a probe signal. Another adaptive filter searches for a transfer function of the modulator by observing an output signal of the quantizer in accordance with the probe signal. A noise cancel circuit cancels a quantization error generated by the quantizer using search results of the adaptive filters.

Abstract: A conventional analog-to-digital conversion circuit has a problem that conversion errors cannot be suppressed.

Abstract: A MASH type sigma delta AD converter includes a modulator, an analog filter filtering an extraction signal obtained by extracting a probe signal and an quantization error generated in a quantizer within a sigma delta modulator, a low speed AD converter performing an AD conversion of an output signal of the analog filter, a first adaptive filter searching for a transfer function of the sigma delta modulator, a second adaptive filter searching for a transfer function from an output of the modulator to the low speed AD converter via the analog filter, and a noise cancellation circuit cancelling the probe signal and the quantization error included in an output signal of the quantizer using the search results by the first and second adaptive filters.

Abstract: A modulator includes an analog integrator including an analog circuit and a quantizer quantizing its output signal. An external input signal is input thereto. A modulator is coupled to the latter stage of the modulator, and includes a quantizer. A probe signal generation circuit injects a probe signal to the modulator. An adaptive filter searches for a transfer function of the modulator by observing an output signal of the quantizer in accordance with a probe signal. Another adaptive filter searches for a transfer function of the modulator by observing an output signal of the quantizer in accordance with the probe signal. A noise cancel circuit cancels a quantization error generated by the quantizer using search results of the adaptive filters.

Abstract: A processing speed can be improved while the accuracy of AD conversion is enhanced. An AD converter includes: a higher-order DAC that samples an analog input signal and performs DA conversion corresponding to higher-order bits of a digital output signal; an extension DAC that performs DA conversion to positive and negative polarities on an extension bit for expanding bits of the higher-order DAC; a lower-order DAC that performs DA conversion corresponding to lower-order bits of the digital output signal; a comparator that compares a comparison reference voltage with output voltages of the higher-order DAC, the extension DAC, and the lower-order DAC; and a successive approximation logic that controls successive approximation performed by the higher-order DAC, the extension DAC, and the lower-order DAC based on a comparison result of the comparator and generates the digital output signal.

Abstract: To improve resolution of a built-in A/D converter by reducing the area occupied by a chip of the built-in A/D converter in a semiconductor integrated circuit that is mounted in an on-vehicle millimeter wave radar device and which incorporates an A/D converter and an MPU. In the semiconductor integrated circuit, a plurality of reception signals of the radar device is A/D-converted by a single digital correction type A/D converter. The digital correction type A/D converter of the single A/D converter is a foreground digital correction type A/D converter that sequentially A/D-converts the reception signals output from a multiplexer of a receiving interface. The single A/D converter includes a pipeline type A/D converter having a plurality of cascade-coupled converters. The semiconductor integrated circuit comprises a correction signal generating unit, a digital correction D/A converter, and a digital correction unit for digital correction.

Abstract: To improve resolution of a built-in A/D converter by reducing the area occupied by a chip of the built-in A/D converter in a semiconductor integrated circuit that is mounted in an on-vehicle millimeter wave radar device and which incorporates an A/D converter and an MPU. In the semiconductor integrated circuit, a plurality of reception signals of the radar device is A/D-converted by a single digital correction type A/D converter. The digital correction type A/D converter of the single A/D converter is a foreground digital correction type A/D converter that sequentially A/D-converts the reception signals output from a multiplexer of a receiving interface. The single A/D converter includes a pipeline type A/D converter having a plurality of cascade-coupled converters. The semiconductor integrated circuit comprises a correction signal generating unit, a digital correction D/A converter, and a digital correction unit for digital correction.

Abstract: A screening tool and a screening method for a therapeutic agent for type II diabetes, particularly an agent for alleviating insulin resistance are disclosed. A novel polypeptide, a polynucleotide, a vector, a promoter, and a transformant which are useful in the screening tool and the screening method, are also disclosed.

Abstract: A screening tool and a screening method for a therapeutic agent for type II diabetes, particularly an agent for alleviating insulin resistance are disclosed. A novel polypeptide, a polynucleotide, a vector, a promoter, and a transformant which are useful in the screening tool and the screening method, are also disclosed.

Abstract: A screening tool and a screening method for a therapeutic agent for type II diabetes, particularly an agent for alleviating insulin resistance are disclosed. A novel polypeptide, a polynucleotide, a vector, a promoter, and a transformant which are useful in the screening tool and the screening method, are also disclosed.

Abstract: A screening tool and a screening method for a therapeutic agent for type II diabetes, particularly an agent for alleviating insulin resistance are disclosed. A novel polypeptide, a polynucleotide, a vector, a promoter, and a transformant which are useful in the screening tool and the screening method, are also disclosed.

Abstract: Amide derivatives represented by general formula (I) or salts thereof wherein each symbol has the following meaning: ring B: an optionally substituted heteroaryl optionally fused with a benzene ring; X: a bond, lower alkylene or lower alkenylene optionally substituted by hydroxy or lower alkyl, carbonyl, or a group represented by —NH— (when X is lower alkylene optionally substituted by lower alkyl which may be bonded to the hydrogen atom bonded to a constituent carbon atom of ring B to form lower alkylene to thereby form a ring); A: a lower alkylene or a group represented by -(lower alkylene)—O—; R1a and R1b: the same or different and each hydrogen or lower alkyl; R2: hydrogen or halogeno; and Z: nitrogen or a group represented by ═CH—.

Abstract: An amide derivative represented by the following general formula (I) or a salt thereof and a pharmaceutical composition containing the amide derivative and a pharmaceutically acceptable vehicle. The symbols in the formula have the following meanings wherein A: heteroarylene; X: bond, O, S, —NR5—, —NR5CO—, —NR5CONH—, —NR5SO2— or —NR5C(═NH)NH—; R1: —H, -optionally substituted lower alkyl, -optionally substituted aryl, -optionally substituted heteroaryl or -optionally substituted cycloalkyl; R2a, R2b: —H or -lower alkyl, which may be the same or different; R3: —H or -lower alkyl; R4a, R4b: —H or —OH, which may be the same different, or R4a and R4b are taken together to form ═O or ═N—O—lower alkyl; and R5: —H or -lower alkyl.

Abstract: An amide derivative represented by the following general formula (I) or a salt thereof and a pharmaceutical composition containing the amide derivative and a pharmaceutically acceptable vehicle. ##STR1## (The symbols in the formula have the following meanings. (whereinA: heteroarylene;X: bond, O, S, --NR.sup.5 --, --NR.sup.5 CO--, --NR.sup.5 CONH--, --NR.sup.5 SO.sub.2 -- or --NR.sup.5 C(.dbd.NH)NH--;R.sup.1 : --H, -optionally substituted lower alkyl, -optionally substituted aryl, -optionally substituted heteroaryl or -optionally substituted cycloalkyl;R.sup.2a, R.sup.2b : --H or -lower alkyl, which may be the same or different;R.sup.3 : --H or -lower alkyl;R.sup.4a, R.sup.4b : --H or --OH, which may be the same different, or R.sup.4a and R.sup.4b are taken together to form .dbd.O or .dbd.N.about.O-lower alkyl; andR.sup.5 : --H or -lower alkyl.

Abstract: Provision of a succinamic acid compound of the formula (1) ##STR1## wherein R.sup.1 is an alkyl or a lower alkenyl and R.sup.2 is an optionally esterified carboxyl, a pharmaceutically acceptable salt thereof, an agent for the prophylaxis and/or treatment of the complications of diabetes, comprising, as an active ingredient, the succinamic acid compound or a pharmaceutically acceptable salt thereof, an aldose reductase inhibitor comprising, as an active ingredient, the succinamic acid compound or a pharmaceutically acceptable salt thereof, and a method for producing the succinamic acid compound or a pharmaceutically acceptable salt thereof. The novel succinamic acid compounds of the formula (1) of the present invention and pharmaceutically acceptable salts thereof have a strong aldose reductase activity-inhibitory in mammals such as human, and show superior safety.

Abstract: A pyridothiazineacetic acid compound of the formula (I) ##STR1## wherein each symbol is as defined in the specification, a pharmaceutically acceptable salt thereof, production thereof, and a pharmaceutical composition, an aldose reductase inhibitor and a preparation for the prevention and treatment of the complications of diabetes, containing the same.The pyridothiazineacetic acid compound and a pharmaceutically acceptable salt thereof of the present invention have an aldose reductase inhibitory action and are superior in safety. Accordingly, they are useful as a preparation for the prevention and treatment of the complications of diabetes, such as faulty union of corneal injury, cataract, neurosis, retinopathy and nephropathy, particularly, cataract and neurosis. In addition, the production method of the present invention enables efficient production of said pyridothiazineacetic acid compound.

Abstract: A 1,4-benzoxazine-2-acetic acid compound of the formula (I) ##STR1## wherein each symbol is as defined in the specification, a pharmaceutically acceptable salt thereof, a method for production thereof, and a pharmaceutical composition, an aldose reductase inhibitor and an agent for the prevention and/or treatment of the complications of diabetes, which contain the same. The compound (I) of the present invention and pharmaceutically acceptable salts thereof have aldose reductase inhibitory action and are superior in safety. Accordingly, they are useful as an agent for the prevention and/or treatment of the complications of diabetes such as faulty union of corneal injury, cataract, neurosis, retinopathy and nephropathy, in particular, cataract and neurosis.

Abstract: A quinoline-3-acetic acid derivative of the formula ##STR1## wherein R.sup.1, R.sup.2 and R.sup.3 are the same or different and each is a hydrogen atom or a halogen atom, R.sup.4 is a hydrogen atom, a halogen atom or a substituted or unsubstituted lower alkyl, R.sup.5 is an optionally esterified carboxyl and the broken line means an optional presence of a double bond, and a pharmaceutically acceptable salt thereof. The novel compound of the formula (I) and a pharmaceutically acceptable salt thereof of the present invention have an aldose reductase inhibitory activity in mammals inclusive of human and are highly safe. Accordingly, they are useful as pharmaceutical compositions for the treatment of the complications of diabetes, such as faulty union of corneal injury, cataract, neurosis, retinopathy and nephropathy, particularly cataract and neurosis.